Literature DB >> 9605787

Effect of warfarin on activated partial thromboplastin time in patients receiving heparin.

C Kearon1, M Johnston, K Moffat, J McGinnis, J S Ginsberg.   

Abstract

BACKGROUND: The activated partial thromboplastin time (APTT) is used to adjust heparin sodium dosage. However, warfarin sodium is often administered concomitantly with heparin and may also affect the APTT and, therefore, heparin dose. We performed a prospective cohort study to quantify the effect of warfarin on the APTT in patients who are being treated with heparin.
METHODS: Serial assays of APTT, international normalized ratio, heparin levels, and functional levels of prothrombin (factor II) and factors VII and X were performed in 24 patients with acute venous thromboembolism who were treated with concomitant continuous intravenous heparin and warfarin. The effects of warfarin, as expressed by international normalized ratio and coagulation factor levels, on APTT were determined.
RESULTS: Warfarin markedly affected APTT; for each increase of 1.0 in the international normalized ratio, the APTT increased 16 seconds (95% confidence interval, 10-22 seconds). The effects of warfarin and heparin on APTT were additive. Consequently, warfarin markedly altered the relationship between APTT and heparin levels; of the 29 blood samples with supratherapeutic APTT, 13 had a therapeutic heparin level and 10 had a subtherapeutic heparin level.
CONCLUSIONS: In patients receiving concomitant heparin and warfarin therapy, APTT reflects the combined effects of both drugs. Because of the marked effect of warfarin on the APTT, decreasing heparin dose in response to a high APTT frequently results in subtherapeutic heparin levels.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9605787     DOI: 10.1001/archinte.158.10.1140

Source DB:  PubMed          Journal:  Arch Intern Med        ISSN: 0003-9926


  7 in total

1.  Diffuse alveolar haemorrhage secondary to warfarin therapy for atrial fibrillation: a case report and literature review.

Authors:  Abdelkarim Waness; Tarek Aldabbagh; Mohammed Harakati
Journal:  BMJ Case Rep       Date:  2009-03-17

2.  Interaction of vitamin K antagonists with heparin affect monitoring by activated clotting times.

Authors:  Jorg Muntwyler; Christine H Attenhofer Jost; Werner Diefenbacher; Jürg H Beer; Rada Nikolic; Feri Amanpour; Anja Faeh-Gunz; Barbara Naegeli; Edwin H Straumann; Dominik Maurer; Reto Candinas; Lam Dang; Christoph Scharf
Journal:  J Interv Card Electrophysiol       Date:  2010-01-20       Impact factor: 1.900

3.  Heparin-induced thrombocytopenia: 2008 update.

Authors:  John R Bartholomew
Journal:  Curr Treat Options Cardiovasc Med       Date:  2008-04

4.  Monitoring of anticoagulant therapy in heart disease: considerations for the current assays.

Authors:  Mohammadali Boroumand; Hamidreza Goodarzynejad
Journal:  J Tehran Heart Cent       Date:  2010-05-31

5.  Postoperative phlegmasia caerulea dolens: a case report and consideration of potential iatrogenic factors.

Authors:  Ronan A Cahill; Hp Redmond
Journal:  J Med Case Rep       Date:  2007-12-01

Review 6.  Hemostatic complications associated with ventricular assist devices.

Authors:  Talal Hilal; James Mudd; Thomas G DeLoughery
Journal:  Res Pract Thromb Haemost       Date:  2019-06-09

7.  Synthetic cannabinoid-associated coagulopathy secondary to long-acting anticoagulant rodenticides: Observational case series and management recommendations.

Authors:  Mona N Bahouth; Peggy Kraus; Kathryn Dane; Manuela Plazas Montana; William Tsao; Burton Tabaac; Jagar Jasem; Holly Schmidlin; Evan Einstein; Michael B Streiff; Satish Shanbhag
Journal:  Medicine (Baltimore)       Date:  2019-09       Impact factor: 1.817

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.